Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : CBSET
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
Details : The objective of this pilot study is to assess microcatheter-based delivery of CypCaps in the pancreatic arterial system. volume of dose, number of CypCaps, and treatment location will be evaluated using imaging and histology.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : CBSET
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Heidelberg Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
Details : The study has achieved positive interim results in its study to establish a malignant ascites mouse model which will form the basis for further testing of the effectiveness of its CypCaps plus ifosfamide pancreatic cancer therapy for the treatment of mal...
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 19, 2022
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Heidelberg Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CypCaps showed, no evidence of toxicity in this animal study in any of the parameters examined and that the study confirms previous data that the capsule material is inert.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 19, 2022
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
Details : CypCaps are genetically engineered human cells, specifically engineered to treat unresectable pancreatic cancer, and encapsulated using PharmaCyte's Cell-in-a-Box technology.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 13, 2022
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaCyte Biotech Study Proves Capsule Material is Not Toxic for Encapsulated Cells
Details : Study demonstrates that the CypCap capsule material is not in any way toxic to encapsulated live cells, the material is bio-inert and used to treat locally advanced, inoperable pancreatic cancer.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The significance of this timepoint is that CypCaps (encapsulated live cells converting ifosamide) has now demonstrated that it has a shelf life of at least 24 months when stored at -80 degree, also maintain viability, enzymatic activity and cell potency.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
Details : PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active (Ifosfamide) or “cancer-killing” form.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
Details : PharmaCyte uses for locally advanced, inoperable pancreatic cancer—Cell-in-a-Box (CypCaps™) combined with the cancer killing prodrug ifosfamide—can also delay the rate of production and accumulation of malignant ascites.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $15.0 million
Deal Type : Public Offering
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
Details : PharmaCyte's CypCapsTM, is a genetically engineered human cells encapsulated using the Cell-in-a-Box® technology. PharmaCyte is conducting a Phase 2b study to evaluate the efficacy and safety of CypCaps in combination with low-dose ifosfamide vs chemora...
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 08, 2021
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : H.C. Wainwright & Co
Deal Size : $15.0 million
Deal Type : Public Offering
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Analysis after 18 months in storage at -80oC, the unfrozen CypCaps product passed all the specified tests, including cell viability, enzyme activity, cell potency, pH, label check, capsule appearance and integrity.
Product Name : CypCaps
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : Encapsulated Live Cell Ifosamide Prodrug,Ifosfamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable